Gene therapies using recombinant adeno associated (rAAV) viral vectors are offering cures for conditions once thought untreatable, but the enormous cost and complex manufacturing keep them out of reach for many patients. In this episode of The BioDisruptors Podcast, we look at a new manufacturing approach that could change the economics of these treatments.

Examining recent research from experts in process development, we explore how a multivariate design of experiments boosted viral vector yields to over one trillion vector genomes per milliliter while improving quality. From the science behind vector production to the impact on dose availability and affordability, we break down how smarter process optimization could make large scale, cost effective gene therapy manufacturing a reality.

Featured Article:  High-Yield Recombinant Adeno-Associated Viral Vector Production by Multivariate Optimization of Bioprocess and Transfection Conditions (https://doi.org/10.1002/btpr.3445)